Drug Profile
Pitavastatin/valsartan - JW Pharmaceutical
Alternative Names: JW 0101 + C 2102; LivaloV; Livasartan; Valsartan/pitavastatin - JW PharmaceuticalLatest Information Update: 19 Jul 2023
Price :
$50
*
At a glance
- Originator JW Pharmaceutical
- Class Antihyperlipidaemics; Antihypertensives; Branched-chain amino acids; Carboxylic acids; Cardiovascular therapies; Cyclopropanes; Fluorobenzenes; Quinolines; Small molecules; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Hyperlipidaemia; Hypertension
- No development reported Hypercholesterolaemia
Most Recent Events
- 18 Jul 2023 Launched for Hyperlipidaemia in South Korea (PO) prior to July 2023 (JW Pharmaceutical pipeline, July 2023)
- 18 Jul 2023 Launched for Hypertension in South Korea (PO) prior to July 2023 (JW Pharmaceutical pipeline, July 2023)
- 28 Aug 2021 No recent reports of development identified for clinical-Phase-Unknown development in Hypercholesterolaemia in South Korea (PO)